Reuters logo
Sanofi wins diabetes drug approval in Japan
June 28, 2013 / 6:16 AM / in 4 years

Sanofi wins diabetes drug approval in Japan

PARIS (Reuters) - French drugmaker Sanofi said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin.

Lyxumia is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic’s blood sugar level climbs too high.

Lyxumia is now approved in Mexico, the European Union, Australia and Japan, Sanofi said in a statement on Friday. A new drug application for lixisenatide in the United States is currently being reviewed, it added.

Reporting by James Regan; Editing by Dominique Vidalon

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below